Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have changed diabetes and obesity treatment by mimicking the gut hormone that signals fullness, boosts insulin secretion, and suppresses glucagon. For many years, these drugs were only available as injections and required cold storage, training on device use, and weekly or daily shots.
With the launch of the first tablet form, semaglutide (Rybelsus), and the development of oral non-peptide molecules like orforglipron, people wonder whether pills could replace pens. This article compares GLP-1 pills vs. injections and discusses the future of these therapies.
What are GLP-1 receptor agonists?
GLP-1 is a natural hormone that the gut releases after you eat. It helps the body release insulin when blood sugar rises, lowers another hormone called glucagon, slows how quickly food leaves the stomach, and tells the brain that you are full. Together, these effects help control blood sugar and reduce appetite.
Because the natural hormone breaks down very quickly in the body, scientists created medications that copy its effects but last much longer.
Injectable GLP-1 RAs
Most GLP-1 medications, including semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide, are given as subcutaneous injections. This means the medicine is injected under the skin, usually once a day or once a week, depending on the drug.
These medications come in prefilled injection pens that work similarly to an insulin pen. The pen already contains the medicine, so you simply attach a small needle, set the dose if required, and inject it into your skin.
Some pens are designed for one-time use, meaning you throw away the entire pen after a single injection. Others are multi-dose pens that hold enough medication for several injections over multiple days or weeks.
Healthcare guidelines recommend rotating injection sites to prevent skin irritation, and a new needle should be used for every injection. Common areas to inject include the abdomen, thigh, or upper arm.
Before the first use, the pens must be stored in the refrigerator between 36°F and 46°F (2-8°C). After opening, many products can be kept at room temperature for about 30 to 56 days, depending on the medication. Exposure to temperatures outside these ranges can damage the drug and make it less effective.
Oral GLP-1 RAs
Currently available oral GLP-1 medications include Rybelsus for type 2 diabetes and Wegovy tablets for weight management. Both contain semaglutide, the same active ingredient used in some injectable GLP-1 drugs.
Because the vast majority of currently approved GLP-1 RAs on the market are peptide-based, they can easily break down in the stomach. To prevent that, the tablets are formulated to include an absorption enhancer called SNAC, which helps the medication pass through the stomach lining and enter the bloodstream.
To help the medicine work properly, the tablet is taken first thing in the morning on an empty stomach with no more than 4 ounces of water. Users would also need to wait at least 30 minutes before eating, drinking, or taking other medications.
These tablets don’t require refrigeration and can be stored at room temperature in their original bottle.
Non-peptide oral GLP-1 RAs
Researchers are now developing a newer type of GLP-1 drug called non-peptide oral GLP-1 RAs. Unlike semaglutide tablets, these medicines are small molecules designed to mimic the effects of the GLP-1 hormone without using a peptide structure.
Because of this design, they may avoid some of the limitations seen with current oral GLP-1 drugs. For example, these medications are more stable in the digestive system, which means they may not require strict fasting instructions or water restrictions when taken.
One of the most advanced drugs in this category is orforglipron, developed by Eli Lilly. It is currently in phase 3 clinical trials for both type 2 diabetes and obesity. Early studies have shown promising results for blood sugar control and weight loss. Other non-peptide GLP-1 drugs are also being studied, including GSBR-1290 (aleniglipron) and HS-10535, which are still in earlier stages of development.
Not every drug in this category has succeeded. For example, danuglipron, a similar oral GLP-1 medication being developed by Pfizer, was discontinued after researchers identified concerns about possible liver injury during clinical testing.
If these newer medications prove safe and effective, they could make GLP-1 treatment more convenient overall. They may be easier to store than injectable GLP-1 drugs, and simpler to take than current oral semaglutide tablets.
GLP-1 pills vs. injections for weight loss and diabetes
While both forms contain similar active ingredients, the way you take them, how well they work, and their convenience can differ.
1. Administration differences
One of the biggest differences between GLP-1 pills and injections is how they are taken. Injections are given under the skin on a set schedule, while pills must be swallowed with specific timing and instructions.
Complexity of injections
Injectable GLP-1 drugs require training. You need to learn how to assemble the pen, attach a new needle, prime the device, and inject the medication. Before each dose, the pen should be taken out of the refrigerator, checked for expiration and clarity, and allowed to reach room temperature.
For some people, the idea of injecting medication can feel intimidating. Concerns about using needles or giving the injection incorrectly are fairly common. In one survey of cardiovascular healthcare providers, fear of injections was the most common reason patients declined injectable therapies, reported in about 56.6% of cases. Other reasons included limited education about the medication (26.4%) and concerns about how to administer the dose (15.1%).
Injection-site reactions can also occur. These may include itching, redness, rash, or small nodules at the injection site. Studies suggest these reactions occur in roughly 4% to 16% of patients, depending on the medication. In the same survey mentioned earlier, 21.4% of participants cited local reactions as a potential reason for discontinuing injectable GLP-1 RAs.
Storage considerations
Because injectable GLP-1 RAs are protein-based biologics, they must be refrigerated before first use. For example, Ozempic can be stored in a refrigerator until the expiration date, but must be discarded or used within 56 days once exposed to room temperature. Saxenda and Victoza pens are similarly restricted to 30 days at room temperature after opening.
In contrast, Rybelsus and Wegovy tablets are stable at room temperature and do not require cold chain logistics.
Dosing routines
With oral semaglutide tablets, timing matters a lot. The medication must be taken first thing in the morning on an empty stomach. You swallow the tablet whole with no more than 4 ounces of water, then wait at least 30 minutes before eating, drinking, or taking other medications. The tablet should not be split, crushed, or chewed, and taking it with food can significantly reduce how much of the drug your body absorbs.
Injectable GLP-1 medications usually involve simpler dosing schedules. Many products are taken once weekly, while others are injected once daily. The injection can be given at any time of the day, with or without food. This flexibility often makes injections easier to fit into daily routines compared with the strict timing required for oral semaglutide tablets.
Adherence and persistence
Real-world data suggest that injectable GLP-1 therapies have moderate adherence, with a mean proportion of days covered (PDC) at six months ranging from 58% to 69.5%, and fewer than half of patients achieve high adherence (PDC of 80% or more).
At one year, the highest adherence among injectables was observed with dulaglutide (59.1%), while only 38.8% of injectable semaglutide users were highly adherent.
In the same study, oral semaglutide showed 82.4% mean PDC at one year, and 65.1% of users achieved high adherence. This suggests the convenience of a pill might improve persistence, though confounding factors such as patient selection and insurance coverage may influence these results.
A cross-sectional survey of 600 adults (REVISE study) found that 76.5% initially preferred a daily oral medicine over a weekly injection. Fear of injections and the ability to add another pill were common reasons, while those who preferred injections often cited the convenience of weekly dosing and not wanting another tablet.
2. Efficacy comparisons
Injectable GLP-1 RAs generally produce greater weight loss and glucose control than the currently available oral semaglutide. Because the medication is injected under the skin, it bypasses the digestive system and delivers higher, more consistent drug levels, avoiding the absorption limits seen with oral GLP-1 RAs.
Semaglutide 2.4 mg weekly (Wegovy) achieved nearly 15% average weight loss, and tirzepatide (Zepbound), a dual GLP-1/GIP receptor agonist that is injected weekly have shown 15%-21% weight loss at 72 weeks.
Real-world use of oral semaglutide 14 mg (Rybelsus) resulted in about 5.7% weight loss over one year. Higher-dose oral semaglutide (Wegovy tablet 25 mg) is approaching injection results with 13.6% weight loss in OASIS 4. The investigational drug, orforglipron, produced up to 12.4% weight loss at the 36 mg dose in ATTAIN 1.
The weight loss with oral GLP-1s remains lower than that seen with injectable tirzepatide and semaglutide.
When used for type 2 diabetes, clinical trials have shown that injectable semaglutide (Ozempic) typically lowers HbA1c by about 1.5% to 2.0%, depending on the dose and patient population. In comparison, oral semaglutide (Rybelsus) generally lowers HbA1c by about 1.0% to 1.5% in similar studies.
3. Safety and tolerability
Gastrointestinal adverse events, such as nausea, vomiting, diarrhea, abdominal pain, and constipation, are the most common side effects across both oral and injectable GLP-1 drugs. These symptoms often occur during dose escalation and subside over time.
Injection-site reactions occur only with injectables. They include pruritus, rash, and nodules, and were reported in up to 16% of participants in trials.
In the ATTAIN-1 trial, 5.3-10.3% of participants discontinued orforglipron due to adverse events, while ~8-10% discontinued in ACHIEVE 3.
In a real-world study, side effects were reported more often in people taking oral semaglutide than in those using the injectable version (16.7% vs 4.9%). Because of this, more people stopped taking the pill due to side effects compared with the injection.
4. Patient perspective
People considering GLP-1 therapy weigh convenience, fear of injections, and frequency of dosing.
In the REVISE survey, 71.7% of respondents who chose the oral option cited concern about using an injectable medication, and over half appreciated that they were already taking tablets. Among those who preferred injections, 89.4% liked that the injection is given once a week instead of daily.
Healthcare professionals report that fear of injections is a major barrier to initiating injectable therapies (56.6%) and that local reactions and side effects are common reasons for discontinuation.
These findings support the need for multiple treatment options to suit different preferences.
5. Access and cost considerations
Both formats are expensive without insurance. In the US, a month’s supply of oral and injectable semaglutide can cost around $900-$1,000 per month at list price. Injectable obesity treatments such as Wegovy may cost even more, often over $1,000 per month, depending on the dose and pharmacy.
Coverage often depends on the medical indication. GLP-1 drugs prescribed for type 2 diabetes are more commonly covered by insurance plans, while those prescribed primarily for weight management are frequently excluded or require stricter eligibility criteria.
Pill formulations may expand access in practical ways. Tablets can be easier to ship, store, and distribute than refrigerated injection pens. Oral agents could also reduce ancillary costs associated with cold chain storage and injection supplies.
Bottom line
At present, GLP-1 injections deliver the greatest weight loss, blood sugar control, and proven cardiovascular benefits compared to pills, but they require training, refrigeration, and can cause injection-site reactions.
It is likely that oral and injectable GLP-1 therapies will coexist. Patients with significant weight loss goals or cardiovascular disease may continue to benefit from high-potency injections such as semaglutide and tirzepatide. Those with needle phobia or lifestyle constraints could choose oral options.
As new GLP-1 pills enter the market, you may see more options for managing weight and blood sugar. The best choice will depend on effectiveness, safety, cost, and what feels most comfortable for you.
Frequently Asked Questions
Related Articles
Sources
Pfizer Inc. (n.d.). Pfizer provides update on oral GLP-1 receptor agonist Danuglipron | Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-oral-glp-1-receptor-agonist
Khatib, R., Angus, N., Hansen, T. B., Lambrinou, E., Vellone, E., Khan, M., & Lee, G. A. (2021). Perceptions of injectable therapies with cardiovascular benefit: an ACNAP survey of healthcare professionals to explore facilitators and barriers. European Journal of Cardiovascular Nursing, 21(5), 430–437. https://doi.org/10.1093/eurjcn/zvab106
Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud. 2014 Fall-Winter;11(3-4):202-30. doi: 10.1900/RDS.2014.11.202. Epub 2015 Feb 10. PMID: 26177483; PMCID: PMC5397288. https://pmc.ncbi.nlm.nih.gov/articles/PMC5397288/
GLP-1 RAS Storage & Stability | Scientific Exchange. (n.d.). https://www.novonordiskmedical.com/product-information/storage-and-stability/glp-1-ras.html
Wang, S. Y., Stofer, R., Wang, H., Brent, G. A., Shi, L., Cai, Y., Roosan, M., & Moin, T. (2025). Bridging efficacy and adherence in Glucagon-Like Peptide-1 Receptor Agonist therapy: The Emerging role of Oral Agents. Diabetes & Metabolism Journal, 49(6), 1331–1333. https://doi.org/10.4093/dmj.2025.0666
Boye, K., Ross, M., Mody, R., Konig, M., & Gelhorn, H. (2020). Patients’ preferences for once?daily oral versus once?weekly injectable diabetes medications: The REVISE study. Diabetes Obesity and Metabolism, 23(2), 508–519. https://doi.org/10.1111/dom.14244
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/nejmoa2206038
Krajnc, M., Kuhar, N., & Koceva, A. (2025). Oral semaglutide for the treatment of obesity: a retrospective real-world study. Frontiers in Endocrinology, 16, 1593334. https://doi.org/10.3389/fendo.2025.1593334
Wharton, S., Lingvay, I., Bogdanski, P., Vale, R. D. D., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., & Garvey, W. T. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine, 393(11), 1077–1087. https://doi.org/10.1056/nejmoa2500969
Lilly’s oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine | Eli Lilly and Company. (n.d.). Eli Lilly and Company. https://lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-meaningful-weight
What is Ozempic®? | Ozempic® (semaglutide) injection. (n.d.). https://www.ozempic.com/why-ozempic/what-is-ozempic.html
Pratley RE, Crowley MJ, Gislum M, Hertz CL, Jensen TB, Khunti K, Mosenzon O, Buse JB. Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. Diabetes Ther. 2021 Apr;12(4):1099-1116. doi: 10.1007/s13300-020-00994-9. Epub 2021 Mar 4. PMID: 33660198; PMCID: PMC7994454. https://pmc.ncbi.nlm.nih.gov/articles/PMC7994454/
Pinto, M., Brennan, L., Diehl, K., Lin, S., & Heacock, S. (2024). Real-World Comparison of Oral Versus Injectable Semaglutide for the Reduction of Hemoglobin A1C and Weight in Patients with Type 2 Diabetes. Journal of Pharmacy Technology, 41(1), 22–31. https://doi.org/10.1177/87551225241289959
Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet. Eli Lilly. https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar-control-and-weight-loss-compared-to-oral-semaglutide-in-head-to-head-type-2-diabetes-trial-published-in-the-lancet-302697632.html
Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., Allen, S. E., Ahmad, N. N., & Klise, S. R. (2025). Orforglipron, an oral Small-Molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine, 393(18), 1796–1806. https://doi.org/10.1056/nejmoa2511774
